Endothelial biomarkers of thrombosis in critically ill patients with acquired coagulopathy: a prospective cohort study

Biomark Med. 2022 Jun;16(9):663-672. doi: 10.2217/bmm-2021-0576. Epub 2022 May 18.

Abstract

Background: It remains largely unknown whether endothelial biomarkers can be used to predict thromboembolism in critically ill patients with an acquired coagulopathy. Materials & methods: The ability of syndecan-1, P-selectin and microRNA expressions to predict thromboembolism were assessed in 40 critically ill coagulopathic patients. Results: The area under the receiver operating characteristic curves for syndecan-1, P-selectin and the four differentially expressed microRNAs - determined by real-time qPCR analysis - to predict thromboembolism (n = 10, 25%) were 0.71 (95% CI: 0.52-0.89), 0.73 (95% CI: 0.52-0.95) and >0.80, respectively. Syndecan-1 and P-selectin concentrations were also significantly correlated with one another (R = 0.41, p = 0.008). Conclusion: Endothelial function biomarkers, including endothelial microRNA expressions, were associated with subsequent thromboembolism in critically ill patients who had a deranged coagulation profile.

Keywords: biomarker; endothelial dysfunction; miRNA; microRNA; thromboembolism; thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Critical Illness
  • Humans
  • MicroRNAs*
  • P-Selectin
  • Prospective Studies
  • Syndecan-1
  • Thromboembolism*
  • Thrombosis*

Substances

  • Biomarkers
  • MicroRNAs
  • P-Selectin
  • Syndecan-1